MALVERN, Pa., Feb. 28 (UPI) -- Novavax and PacificGMP said Tuesday they are teaming on avian-flu vaccine technologies.
Under the deal, the firms will develop a large-scale production process for Novavax's experimental vaccine for avian-flu virus and other biological products, the companies said.
The manufacturing process under development is based on bioprocessing to speed up vaccine production, minimize cross-contamination risks and reduce production costs, they said.
"This agreement with PacificGMP brings another critical capability to Novavax in the development of our H5N1 avian influenza VLP vaccine, and puts Novavax a step closer to servicing the world at large in the event of a pandemic," said Novavax President and Chief Executive Officer Rahul Singhvi.
"To ensure true surge capacity for production of our pandemic influenza vaccine, we have designed our manufacturing process around the use of disposable equipment designed by Wave Biotech LLC," he said.
Novavax said it is currently doing preclinical studies on its avian-flu vaccine.
